JP2017506636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506636A5 JP2017506636A5 JP2016551704A JP2016551704A JP2017506636A5 JP 2017506636 A5 JP2017506636 A5 JP 2017506636A5 JP 2016551704 A JP2016551704 A JP 2016551704A JP 2016551704 A JP2016551704 A JP 2016551704A JP 2017506636 A5 JP2017506636 A5 JP 2017506636A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- immune
- pathological
- endonuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 55
- 210000002865 immune cell Anatomy 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 230000001575 pathological effect Effects 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102100031780 Endonuclease Human genes 0.000 claims description 14
- 108010042407 Endonucleases Proteins 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 8
- 230000000415 inactivating effect Effects 0.000 claims description 8
- -1 CD31 Proteins 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 3
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 3
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 3
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 3
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 102100024263 CD160 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 108090000397 Caspase 3 Proteins 0.000 claims description 2
- 102100026549 Caspase-10 Human genes 0.000 claims description 2
- 102100029855 Caspase-3 Human genes 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 2
- 101000809594 Escherichia coli (strain K12) Shikimate kinase 1 Proteins 0.000 claims description 2
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 2
- 102100040739 Guanylate cyclase soluble subunit beta-1 Human genes 0.000 claims description 2
- 102100028008 Heme oxygenase 2 Human genes 0.000 claims description 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 claims description 2
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 claims description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 2
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 claims description 2
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 2
- 101001038731 Homo sapiens Guanylate cyclase soluble subunit beta-1 Proteins 0.000 claims description 2
- 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 claims description 2
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 claims description 2
- 101001083151 Homo sapiens Interleukin-10 receptor subunit alpha Proteins 0.000 claims description 2
- 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 claims description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 2
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 2
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 claims description 2
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 claims description 2
- 101001068019 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Proteins 0.000 claims description 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 2
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 2
- 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 claims description 2
- 101000863692 Homo sapiens Ski oncogene Proteins 0.000 claims description 2
- 101000688996 Homo sapiens Ski-like protein Proteins 0.000 claims description 2
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 2
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 claims description 2
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 claims description 2
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 2
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 claims description 2
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 2
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims description 2
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 2
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims description 2
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims description 2
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 claims description 2
- 102100034470 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Human genes 0.000 claims description 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 2
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 2
- 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 claims description 2
- 102100029969 Ski oncogene Human genes 0.000 claims description 2
- 102100024451 Ski-like protein Human genes 0.000 claims description 2
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 108091007178 TNFRSF10A Proteins 0.000 claims description 2
- 108700019146 Transgenes Proteins 0.000 claims description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 2
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 claims description 2
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 claims description 2
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims 1
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 1
- 102100022749 Aminopeptidase N Human genes 0.000 claims 1
- 102000008682 Argonaute Proteins Human genes 0.000 claims 1
- 108010088141 Argonaute Proteins Proteins 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- 102100037917 CD109 antigen Human genes 0.000 claims 1
- 102100021992 CD209 antigen Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100036008 CD48 antigen Human genes 0.000 claims 1
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 1
- 102100025222 CD63 antigen Human genes 0.000 claims 1
- 102100027221 CD81 antigen Human genes 0.000 claims 1
- 102100027217 CD82 antigen Human genes 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102000024905 CD99 Human genes 0.000 claims 1
- 108060001253 CD99 Proteins 0.000 claims 1
- 102100038918 Caspase-6 Human genes 0.000 claims 1
- 102100038902 Caspase-7 Human genes 0.000 claims 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 claims 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims 1
- 108700023863 Gene Components Proteins 0.000 claims 1
- 102100040754 Guanylate cyclase soluble subunit alpha-1 Human genes 0.000 claims 1
- 102100040735 Guanylate cyclase soluble subunit alpha-2 Human genes 0.000 claims 1
- 102100028963 Guanylate cyclase soluble subunit beta-2 Human genes 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 claims 1
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 claims 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 claims 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims 1
- 101001038755 Homo sapiens Guanylate cyclase soluble subunit alpha-1 Proteins 0.000 claims 1
- 101001038749 Homo sapiens Guanylate cyclase soluble subunit alpha-2 Proteins 0.000 claims 1
- 101001059095 Homo sapiens Guanylate cyclase soluble subunit beta-2 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 101000604993 Homo sapiens Lysosome-associated membrane glycoprotein 2 Proteins 0.000 claims 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000650817 Homo sapiens Semaphorin-4D Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims 1
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 claims 1
- 102100022341 Integrin alpha-E Human genes 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 claims 1
- 102100039564 Leukosialin Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 claims 1
- 102100025136 Macrosialin Human genes 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100027744 Semaphorin-4D Human genes 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470076 | 2014-02-14 | ||
| DKPA201470076 | 2014-02-14 | ||
| PCT/EP2015/053162 WO2015121454A1 (en) | 2014-02-14 | 2015-02-13 | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506636A JP2017506636A (ja) | 2017-03-09 |
| JP2017506636A5 true JP2017506636A5 (cg-RX-API-DMAC7.html) | 2018-03-15 |
| JP6673838B2 JP6673838B2 (ja) | 2020-04-01 |
Family
ID=50114255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551704A Active JP6673838B2 (ja) | 2014-02-14 | 2015-02-13 | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 |
Country Status (19)
Families Citing this family (194)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| JP6976058B2 (ja) * | 2013-11-22 | 2021-12-01 | セレクティスCellectis | 免疫療法のための化学療法薬耐性t細胞を工学的に作製する方法 |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Cd33キメラ抗原受容体を使用する癌の処置 |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| AU2015357535B2 (en) | 2014-12-05 | 2020-05-14 | Eureka Therapeutics, Inc. | Antibodies targeting G-protein coupled receptor and methods of use |
| CN107429253B (zh) * | 2014-12-05 | 2021-11-05 | 希望之城公司 | Cs1靶向性嵌合抗原受体修饰的t细胞 |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| HRP20220890T1 (hr) | 2015-02-06 | 2022-10-14 | National University Of Singapore | Postupci za povećanje učinkovitosti terapijskih imunosnih stanica |
| EP3062105A1 (en) * | 2015-02-26 | 2016-08-31 | Université de Bretagne Occidentale (U.B.O.) | Processes for the diagnosis, prognosis and monitoring of the progression of Chronic Lymphoid Leukaemia (CLL) and/or of Systemic Lupus Erythematosus (SLE) using membrane STIM 1 |
| CA2977106A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| WO2016142532A1 (en) | 2015-03-11 | 2016-09-15 | Cellectis | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| US12121539B2 (en) * | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| AU2016326734B2 (en) | 2015-09-25 | 2022-07-07 | Abvitro Llc | High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences |
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| ES2803728T3 (es) | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| IL258491B2 (en) * | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| EP3368571B1 (en) | 2015-10-30 | 2022-12-07 | The Regents of The University of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体の皮下製剤及びその使用 |
| US12642852B1 (en) * | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| CA3005753A1 (en) * | 2015-11-19 | 2017-06-29 | Bloodcenter Research Foundation | Method of manufacturing dual-specific t-cells for use in cancer immunotherapy |
| CN105368859B (zh) * | 2015-11-25 | 2019-10-18 | 王任直 | 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用 |
| EP3418304B1 (en) * | 2016-02-15 | 2021-08-04 | Kanagawa Prefectural Hospital Organization | Recognition of membrane type mucin-like protein and clinical application thereof |
| CN108699161B (zh) * | 2016-03-04 | 2022-06-03 | 莫佛塞斯公司 | 多发性骨髓瘤中m-蛋白应答的临床评估 |
| WO2017177175A1 (en) * | 2016-04-07 | 2017-10-12 | The George Washington University | Methods and compositions targeting retroviral latency |
| WO2017177337A1 (en) * | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| WO2017178586A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
| US10894093B2 (en) | 2016-04-15 | 2021-01-19 | Cellectis | Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
| EP3452499A2 (en) * | 2016-05-06 | 2019-03-13 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| WO2017214569A1 (en) * | 2016-06-09 | 2017-12-14 | Regents Of The University Of Minnesota | Genome-edited nk cell and methods of making and using |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| US12012598B2 (en) | 2016-08-12 | 2024-06-18 | Toolgen Incorporated | Manipulated immunoregulatory element and immunity altered thereby |
| IL264439B2 (en) * | 2016-08-17 | 2024-08-01 | Factor Bioscience Inc | non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| CA3039136A1 (en) | 2016-09-02 | 2018-03-08 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| JP7148147B2 (ja) | 2016-10-05 | 2022-10-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ブリオスタチン化合物およびその調製方法 |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| WO2018069927A1 (en) * | 2016-10-10 | 2018-04-19 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| CN106544321B (zh) * | 2016-10-13 | 2019-01-29 | 北京艺妙神州医疗科技有限公司 | 通用型car-t细胞及其制备方法和用途 |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| CA3042179A1 (en) * | 2016-10-31 | 2018-05-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |
| US11312998B2 (en) * | 2016-11-07 | 2022-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selecting therapy for a cancer patient |
| US11883430B2 (en) * | 2016-11-09 | 2024-01-30 | Musc Foundation For Research Development | CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy |
| DK3321280T3 (da) * | 2016-11-10 | 2021-02-22 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Immunmodulatorer til reduktion af immunresistens i et melanom og andre proliferative sygdomme |
| WO2018087285A1 (en) * | 2016-11-10 | 2018-05-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Or10h1 antigen binding proteins and uses thereof |
| CN118581046A (zh) | 2016-11-22 | 2024-09-03 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| EP3544612A4 (en) * | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
| EP3581190B1 (en) * | 2016-12-09 | 2021-03-10 | ONK Therapeutics Limited | Engineered natural killer cells and uses thereof |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US11541076B2 (en) | 2017-01-13 | 2023-01-03 | Celdara Medical, Llc | Chimeric antigen receptors targeting TIM-1 |
| US10440535B2 (en) | 2017-01-25 | 2019-10-08 | The George Washington University | System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets |
| EP3585817A4 (en) * | 2017-02-22 | 2020-12-02 | Aleta Biotherapeutics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| WO2018156791A1 (en) * | 2017-02-22 | 2018-08-30 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| CN110869046B (zh) | 2017-03-31 | 2025-02-25 | 塞勒克提斯公司 | 通用型抗cd22嵌合抗原受体工程化的免疫细胞 |
| US12275963B2 (en) | 2017-05-08 | 2025-04-15 | Toolgen Incorporated | Artificially manipulated immune cell |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| US12384830B2 (en) * | 2017-06-02 | 2025-08-12 | Regents Of The University Of Minnesota | Compositions and methods for improving immunotherapy |
| CN106978445A (zh) * | 2017-06-12 | 2017-07-25 | 内蒙古大学 | CRISPER‑Cas9系统介导的山羊EDAR基因敲除的方法 |
| CN118853581A (zh) * | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| EP4775669A2 (en) | 2017-06-30 | 2026-07-15 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| AU2018292181B2 (en) | 2017-06-30 | 2025-04-10 | Cellectis | Cellular immunotherapy for repetitive administration |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| CN107312800B (zh) * | 2017-08-01 | 2020-02-07 | 北京舜雷科技有限公司 | 能敲低内源性pd-1表达的cik及其制备方法与应用 |
| CA3071282A1 (en) | 2017-08-10 | 2019-02-14 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| CN107541526B (zh) * | 2017-08-23 | 2019-12-10 | 北京瑞健科技有限公司 | 能敲低内源性ctla4表达的cik及制备方法与应用 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| KR20200076732A (ko) * | 2017-11-03 | 2020-06-29 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd38-지시된 키메라 항원 수용체 작제물 |
| GB201719169D0 (en) | 2017-11-20 | 2018-01-03 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor and ligand |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| BR112020011017A2 (pt) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| WO2019129851A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
| AU2019216269B2 (en) * | 2018-01-30 | 2025-05-01 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen |
| MX2020008183A (es) | 2018-02-01 | 2020-09-22 | Pfizer | Anticuerpos especificos para cd70 y sus usos. |
| MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| WO2019183572A1 (en) * | 2018-03-23 | 2019-09-26 | Refuge Biotechnologies, Inc. | Gene regulation via conditional nuclear localization of gene modulating polypeptides |
| AU2019243315A1 (en) * | 2018-03-29 | 2020-09-24 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| CN112585277A (zh) * | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 表达重组受体的t细胞、相关多核苷酸和方法 |
| KR102617818B1 (ko) | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
| SG11202007878UA (en) | 2018-04-27 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Expression of foxp3 in edited cd34+ cells |
| WO2019210207A2 (en) * | 2018-04-27 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| US12527821B2 (en) | 2018-05-15 | 2026-01-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tumor cell killers and vaccines |
| CN112654710A (zh) | 2018-05-16 | 2021-04-13 | 辛瑟高公司 | 用于指导rna设计和使用的方法和系统 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| JP7584299B2 (ja) | 2018-05-23 | 2024-11-15 | ナショナル ユニバーシティ オブ シンガポール | T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現 |
| CA3103610A1 (en) * | 2018-06-12 | 2019-12-19 | The Regents Of The University Of California | Single-chain bispecific chimeric antigen receptors for the treatment of cancer |
| CN112368021B (zh) | 2018-06-14 | 2025-02-21 | 2赛文缇生物公司 | Cd79a嵌合抗原受体 |
| CN110623980A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| KR20210031898A (ko) * | 2018-07-13 | 2021-03-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 전염병을 치료하기 위한 공동수용체 시스템 |
| CN110819589B (zh) * | 2018-08-13 | 2022-10-11 | 上海科技大学 | 一种增强免疫效应细胞功能的方法 |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| EP3629021A1 (en) * | 2018-09-26 | 2020-04-01 | Euroimmun Medizinische Labordiagnostika AG | Diagnosis of a neuroautoimmune disease |
| EP3860635A4 (en) * | 2018-10-04 | 2022-07-06 | Rutgers, The State University of New Jersey | METHOD OF REDUCING TYPE 2 CYTOKINE MEDIATED INFLAMMATION WITH NEUROMEDIN PEPTIDES |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12624086B2 (en) * | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| WO2020102721A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als) |
| AU2019387377B2 (en) * | 2018-11-30 | 2026-07-09 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD38 immunotherapy |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| JP2022526504A (ja) * | 2019-03-21 | 2022-05-25 | オーエヌケー セラピューティクス リミテッド | 細胞死に対する耐性が増大した改変免疫エフェクター細胞 |
| US20200308296A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
| WO2020194243A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone |
| WO2020194245A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone |
| US20200316197A1 (en) * | 2019-03-28 | 2020-10-08 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone |
| EP4332115A3 (en) | 2019-04-03 | 2024-05-29 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| WO2020236833A1 (en) * | 2019-05-21 | 2020-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin compounds for enhancement of immunotherapy |
| MX2021015495A (es) * | 2019-06-14 | 2022-04-18 | 2Seventy Bio Inc | Composiciones y métodos para tratar cáncer. |
| CN118813654A (zh) | 2019-08-12 | 2024-10-22 | 生命编辑制药股份有限公司 | Rna指导的核酸酶及其活性片段及变体以及使用方法 |
| CA3147835A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors for treating myeloid malignancies |
| PH12022550548A1 (en) * | 2019-09-06 | 2023-11-20 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
| EP4031166A1 (en) * | 2019-09-18 | 2022-07-27 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN114729328B (zh) * | 2019-11-13 | 2024-05-03 | 上海医药集团股份有限公司 | Tmem59蛋白二聚体或嵌合表达受体改善t细胞功能 |
| AU2020382219A1 (en) | 2019-11-13 | 2022-05-12 | Crispr Therapeutics Ag | Manufacturing process for making T cells expressing chimeric antigen receptors |
| WO2021095012A1 (en) * | 2019-11-13 | 2021-05-20 | Crispr Therapeutics Ag | Methods of manufacturing car-t cells |
| US12616734B2 (en) | 2019-11-28 | 2026-05-05 | CentricsBio, Inc. | Chimeric antigen receptor specifically binding to cd 300C antigen or receptor thereof |
| BR112022013445A2 (pt) * | 2020-01-08 | 2022-09-13 | Univ Texas | Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos |
| CN111196858B (zh) * | 2020-02-05 | 2021-02-09 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
| EP4126243A4 (en) * | 2020-03-27 | 2024-06-12 | The Trustees of Indiana University | Immunotherapeutic targets in multiple myeloma and methods for their identification |
| CN115777017A (zh) * | 2020-05-06 | 2023-03-10 | 亘喜生物科技(上海)有限公司 | 用于t细胞工程改造的组合物及方法 |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| MX2022015586A (es) * | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| WO2021260696A1 (en) | 2020-06-22 | 2021-12-30 | Ramot At Tel-Aviv University Ltd. | Multi subunit protein modules, cells expressing same and uses thereof |
| CN111796101B (zh) * | 2020-07-14 | 2022-08-26 | 汕头市中心医院 | Notch3蛋白表达量检测剂联合cypa蛋白表达量检测剂在预测癌症治疗疗效的用途 |
| CN116963771A (zh) * | 2020-12-02 | 2023-10-27 | 托马斯杰弗逊大学 | 桥粒芯蛋白2-定向嵌合抗原受体(car)构建体和使用方法 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| WO2022210487A1 (ja) * | 2021-03-29 | 2022-10-06 | タカラバイオ株式会社 | 抗原に特異的な受容体を発現する免疫細胞の製造方法 |
| IL307498A (en) * | 2021-04-05 | 2023-12-01 | Altheia Science S R L | Diagnosis and treatment of myeloid disorders and acute leukemia using antigens specific to new tumors |
| EP4349858A4 (en) * | 2021-05-24 | 2025-06-11 | CentricsBio, Inc. | CHIMERIC ANTIGEN RECEPTOR SPECIFICALLY BINDING TO THE CD300C ANTIGEN OR ITS RECEPTOR |
| CN113671196B (zh) * | 2021-07-29 | 2023-09-12 | 中国人民解放军空军军医大学 | Lair-1分子与脂联素的相互作用对于t细胞活化作用影响的研究方法 |
| US20250019724A1 (en) * | 2021-11-18 | 2025-01-16 | Correctsequence Therapeutics | Regeneration of surface antigen-negative cells |
| CN114350616A (zh) * | 2022-01-24 | 2022-04-15 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其制备方法和应用 |
| WO2023147293A2 (en) * | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising anti-cd38 chimeric antigen receptors (cars) |
| CN119213026A (zh) * | 2022-03-04 | 2024-12-27 | 耶鲁大学 | 用于治疗和预防纤维化的方法和组合物 |
| EP4482872A4 (en) * | 2022-03-07 | 2026-03-18 | Nkarta Inc | Multiplex gene-edited cells for CD70-led cancer immunotherapy |
| CN114397464B (zh) * | 2022-03-24 | 2022-06-10 | 天津德祥生物技术有限公司 | 一种红细胞膜碎片与载体的偶联复合物、其偶联方法和应用 |
| WO2023194501A1 (en) * | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
| CN114569709B (zh) * | 2022-05-05 | 2022-07-12 | 苏州慧疗生物医药科技有限公司 | 高表达adam-28的黑色素瘤自体肿瘤疫苗的制备方法及其应用 |
| CN115951055B (zh) * | 2022-12-13 | 2024-10-15 | 湖南湘医投蕙尧生命科技有限公司 | 一种癌症相关蛋白及其抗体和应用 |
| WO2024154122A1 (en) | 2023-01-18 | 2024-07-25 | Gilboa Therapeutics LTD | Immune cells expressing a complement receptor and uses thereof |
| TW202515994A (zh) * | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對cd70進行基因修飾之組合物及方法 |
| CN121969385A (zh) | 2023-09-11 | 2026-05-01 | 丹娜-法伯癌症研究院 | 含有il-2变体以增强car t细胞的功能性的car-衔接子 |
| JP2025074700A (ja) * | 2023-10-30 | 2025-05-14 | 学校法人藤田学園 | 抗cd38-carを発現する細胞傷害性免疫担当細胞、その製造方法、および当該免疫担当細胞を含む医薬組成物 |
| CN118108860B (zh) * | 2024-03-07 | 2025-04-29 | 南京澄实生物医药科技有限公司 | 一种基于FcRn可提高细胞免疫水平的重组疫苗及应用 |
| PL249941B1 (pl) * | 2024-04-24 | 2026-07-20 | Univ Lodzki | Preparat biologiczny zawierający limfocyty pozbawione adhezyjnego receptora oddziałującego z białkami G F5 do leczenia chorób nowotworowych przewodu pokarmowego |
| WO2026076403A1 (en) * | 2024-10-03 | 2026-04-09 | New York University | Method, system, and computer-accessible medium for modifying and/or redesigning peptide-centric chimeric antigen receptors (pc-cars) against novel peptide antigens |
| CN119684463B (zh) * | 2024-12-25 | 2025-09-12 | 武汉爱博泰克生物科技有限公司 | 抗人ceacam5蛋白的抗体、抗体对和试剂盒及应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| AU6704794A (en) | 1993-04-13 | 1994-11-08 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US6642043B1 (en) | 1996-03-12 | 2003-11-04 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CN1826408B (zh) | 2003-03-14 | 2011-01-26 | 塞托·帕尔斯科技公司 | 大容量离体电穿孔法 |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| ATE466933T1 (de) | 2005-03-15 | 2010-05-15 | Cellectis | I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| JP5328018B2 (ja) | 2006-06-05 | 2013-10-30 | 国立大学法人広島大学 | 抗cd38抗体を細胞表面に有する免疫担当細胞 |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CN103993012B (zh) | 2007-12-27 | 2023-01-10 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| BRPI1013927A2 (pt) | 2009-05-13 | 2016-04-05 | Genzyme Corp | métodos e composições para o tratamento de lúpus |
| EP2542258A4 (en) * | 2010-03-04 | 2013-08-21 | Vet Therapeutics Inc | ON CD52 MONOCLONAL ANTIBODIES |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| CA2816379A1 (en) | 2010-10-27 | 2012-05-03 | Baylor College Of Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20140115726A1 (en) | 2011-04-05 | 2014-04-24 | Cellectis | New tale-protein scaffolds and uses thereof |
| DK2699593T4 (da) | 2011-04-20 | 2021-02-08 | Univ Washington Through Its Center For Commercialization | Beta-2 mikroglobulin-deficiente celler |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강 |
| EP2877488B1 (en) | 2012-07-24 | 2021-02-24 | Cellectis | New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法 |
| KR102012119B1 (ko) * | 2015-05-15 | 2019-08-19 | 오루 카약 인코포레이티드 | 큰 조종석을 갖는 접이식 카약 |
-
2015
- 2015-02-13 DK DK15706399.1T patent/DK3105317T3/en active
- 2015-02-13 HU HUE15706399A patent/HUE041497T2/hu unknown
- 2015-02-13 KR KR1020167025575A patent/KR102157924B1/ko active Active
- 2015-02-13 EP EP18194851.4A patent/EP3505623B1/en active Active
- 2015-02-13 DK DK18194851.4T patent/DK3505623T3/da active
- 2015-02-13 BR BR112016017806-8A patent/BR112016017806B1/pt active IP Right Grant
- 2015-02-13 PL PL15706399T patent/PL3105317T3/pl unknown
- 2015-02-13 ES ES15706399T patent/ES2711498T3/es active Active
- 2015-02-13 RU RU2016136702A patent/RU2714258C2/ru active
- 2015-02-13 JP JP2016551704A patent/JP6673838B2/ja active Active
- 2015-02-13 AU AU2015216875A patent/AU2015216875B2/en active Active
- 2015-02-13 ES ES18194851T patent/ES3063961T3/es active Active
- 2015-02-13 CA CA2937711A patent/CA2937711C/en active Active
- 2015-02-13 PT PT15706399T patent/PT3105317T/pt unknown
- 2015-02-13 US US15/118,801 patent/US10836998B2/en active Active
- 2015-02-13 MX MX2016010345A patent/MX378913B/es unknown
- 2015-02-13 CN CN201580008739.XA patent/CN106029875B/zh active Active
- 2015-02-13 TR TR2018/19571T patent/TR201819571T4/tr unknown
- 2015-02-13 WO PCT/EP2015/053162 patent/WO2015121454A1/en not_active Ceased
- 2015-02-13 EP EP15706399.1A patent/EP3105317B1/en active Active
-
2016
- 2016-07-07 IL IL246645A patent/IL246645B/en active IP Right Grant
- 2016-08-09 NO NO20161276A patent/NO20161276A1/en unknown
-
2020
- 2020-07-27 US US16/939,466 patent/US11692169B2/en active Active
-
2023
- 2023-05-22 US US18/321,481 patent/US20230357719A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7676472B2 (ja) | 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体 | |
| US20260034195A1 (en) | Chimeric antigen receptors and uses thereof | |
| JP7190096B2 (ja) | 遺伝子編集t細胞及びその使用 | |
| JP6673838B2 (ja) | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 | |
| KR20220047380A (ko) | Cll1 변형을 위한 조성물 및 방법 | |
| JP2004528806A5 (cg-RX-API-DMAC7.html) | ||
| JP2022546505A (ja) | Cd123改変ための組成物および方法 | |
| CN111094358A (zh) | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 | |
| JP2022534813A (ja) | Cd33改変のための組成物および方法 | |
| JP2023541457A (ja) | Cd38修飾のための化合物および方法 | |
| US20240238344A1 (en) | Compositions and methods for cd123 modification | |
| EP4214318A1 (en) | Compositions and methods for cd7 modification | |
| JP2024502820A (ja) | Cd34遺伝子改変のための組成物及び方法 | |
| JP2023540276A (ja) | Cll1改変のための組成物および方法 | |
| US20230364233A1 (en) | Compositions and methods for cd6 modification | |
| JP2022519577A (ja) | 養子細胞移植療法における使用のためのカルシニューリン阻害剤耐性免疫細胞 | |
| EP4430186A1 (en) | Compositions and methods for erm2 modification | |
| KR20230107610A (ko) | 키메라 항원 수용체를 발현하는 유전적으로 조작된 세포와 관련된 방법 및 조성물 | |
| RU2793803C2 (ru) | Иммунологически отличимые варианты поверхности клеток для применения в клеточной терапии | |
| RU2841244C2 (ru) | Химерные антигенные рецепторы и пути их применения | |
| RU2822196C2 (ru) | Способы получения клеток, экспрессирующих химерный антигенный рецептор | |
| CN116744963A (zh) | 与表达嵌合抗原受体的经基因工程化的细胞有关的方法和组合物 | |
| HK40014655A (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| HK40014655B (en) | Immunologically discernible cell surface variants for use in cell therapy |